-
Je něco špatně v tomto záznamu ?
Radiolabeled 15-mer peptide internalization is mediated by megalin (LRP2 receptor) in a CRISPR/Cas9-based LRP2 knockout human kidney cell model
A. Durinova, L. Smutna, P. Barta, R. Kamaraj, T. Smutny, B. Schmierer, P. Pavek, F. Trejtnar
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
CZ.02.01.01/00/22_008/0004607
NETPHARM
150120
Grantová Agentura, Univerzita Karlova
NLK
Directory of Open Access Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
ProQuest Central
od 2016-06-01
Health & Medicine (ProQuest)
od 2016-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2016
Springer Journals Complete - Open Access
od 2017-01-01
Springer Nature OA/Free Journals
od 2017-01-01
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Megalin (LRP2 receptor) mediates the endocytosis of radiolabeled peptides into proximal tubular kidney cells, which may cause nephrotoxicity due to the accumulation of a radioactive tracer. The study aimed to develop a cellular model of human kidney HK2 cells with LRP2 knockout (KO) using CRISPR/Cas9 technique. This model was employed for the determination of the megalin-mediated accumulation of 68Ga- and 99mTc-labeled 15-mer peptide developed to target the vascular endothelial growth factor (VEGF) receptor in oncology radiodiagnostics. RESULTS: The gene editing in the LRP2 KO model was verified by testing two well-known megalin ligands when higher viability of KO cells was observed after gentamicin treatment at cytotoxic concentrations and lower FITC-albumin internalization by the KO cells was detected in accumulation studies. Fluorescent-activated cell sorting was used to separate genetically modified LRP2 KO cell subpopulations. Moreover, flow cytometry with a specific antibody against megalin confirmed LRP2 knockout. The verified KO model identified both 68Ga- and 99mTc-radiolabeled 15-mer peptides as megalin ligands in accumulation studies. We found that both radiolabeled 15-mers enter LRP2 KO HK2 cells to a lesser extent compared to parent cells. Differences in megalin-mediated cellular uptake depending on the radiolabeling were not observed. Using biomolecular docking, the interaction site of the 15-mer with megalin was also described. CONCLUSION: The CRISPR/Cas9 knockout of LRP2 in human kidney HK2 cells is an effective approach for the determination of radiopeptide internalization mediated by megalin. This in vitro method provided direct molecular evidence for the cellular uptake of radiolabeled anti-VEGFR 15-mer peptides via megalin.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24012983
- 003
- CZ-PrNML
- 005
- 20240726151456.0
- 007
- ta
- 008
- 240723s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s41181-024-00262-2 $2 doi
- 035 __
- $a (PubMed)38637347
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Durinova, Anna $u Division of Radiopharmacy, Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 245 10
- $a Radiolabeled 15-mer peptide internalization is mediated by megalin (LRP2 receptor) in a CRISPR/Cas9-based LRP2 knockout human kidney cell model / $c A. Durinova, L. Smutna, P. Barta, R. Kamaraj, T. Smutny, B. Schmierer, P. Pavek, F. Trejtnar
- 520 9_
- $a BACKGROUND: Megalin (LRP2 receptor) mediates the endocytosis of radiolabeled peptides into proximal tubular kidney cells, which may cause nephrotoxicity due to the accumulation of a radioactive tracer. The study aimed to develop a cellular model of human kidney HK2 cells with LRP2 knockout (KO) using CRISPR/Cas9 technique. This model was employed for the determination of the megalin-mediated accumulation of 68Ga- and 99mTc-labeled 15-mer peptide developed to target the vascular endothelial growth factor (VEGF) receptor in oncology radiodiagnostics. RESULTS: The gene editing in the LRP2 KO model was verified by testing two well-known megalin ligands when higher viability of KO cells was observed after gentamicin treatment at cytotoxic concentrations and lower FITC-albumin internalization by the KO cells was detected in accumulation studies. Fluorescent-activated cell sorting was used to separate genetically modified LRP2 KO cell subpopulations. Moreover, flow cytometry with a specific antibody against megalin confirmed LRP2 knockout. The verified KO model identified both 68Ga- and 99mTc-radiolabeled 15-mer peptides as megalin ligands in accumulation studies. We found that both radiolabeled 15-mers enter LRP2 KO HK2 cells to a lesser extent compared to parent cells. Differences in megalin-mediated cellular uptake depending on the radiolabeling were not observed. Using biomolecular docking, the interaction site of the 15-mer with megalin was also described. CONCLUSION: The CRISPR/Cas9 knockout of LRP2 in human kidney HK2 cells is an effective approach for the determination of radiopeptide internalization mediated by megalin. This in vitro method provided direct molecular evidence for the cellular uptake of radiolabeled anti-VEGFR 15-mer peptides via megalin.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Smutna, Lucie $u Division of Radiopharmacy, Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. hyrsl7aa@faf.cuni.cz $1 https://orcid.org/0000000239414193 $7 uk20211104952
- 700 1_
- $a Barta, Pavel $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Kamaraj, Rajamanikkam $u Division of Radiopharmacy, Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Smutny, Tomas $u Division of Radiopharmacy, Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Schmierer, Bernhard $u SciLifeLab and Department of Medical Biochemistry and Biophysics, CRISPR Functional Genomics, Karolinska Institutet, Solna, Sweden
- 700 1_
- $a Pavek, Petr $u Division of Radiopharmacy, Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Trejtnar, Frantisek $u Division of Radiopharmacy, Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 773 0_
- $w MED00214678 $t EJNMMI radiopharmacy and chemistry $x 2365-421X $g Roč. 9, č. 1 (2024), s. 32
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38637347 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151449 $b ABA008
- 999 __
- $a ok $b bmc $g 2125551 $s 1224846
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 9 $c 1 $d 32 $e 20240418 $i 2365-421X $m EJNMMI radiopharmacy and chemistry $n EJNMMI Radiopharm Chem $x MED00214678
- GRA __
- $a CZ.02.01.01/00/22_008/0004607 $p NETPHARM
- GRA __
- $a 150120 $p Grantová Agentura, Univerzita Karlova
- LZP __
- $a Pubmed-20240723